Elliot Norry Biography and Net Worth

Dr. Elliot Norry M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Norry serves as Senior Vice President, Chief Medical Officer of the Company. Elliot Norry serves as Senior Vice President, Chief Medical Officer of the Company. Elliot Norry serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Norry has served as Head of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015. He has been acting Chief Medical Officer since August 2019. Prior to joining Adaptimmune, he served as Safety Development Leader and was Chair of the Hepatic Safety Panel at GSK. Prior to his work in the biotech and pharmaceutical industries, Dr. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania for 13 years. He holds a B.A. from Columbia College and an M.D. from New York University. He performed his residency in Internal Medicine at Temple University Hospital, Philadelphia and GI fellowship at Thomas Jefferson University Hospital, Philadelphia.

What is Elliot Norry's net worth?: The estimated net worth of Elliot Norry is at least $2,235.39 as of January 16th, 2024. Dr. Norry owns 3,363 shares of Adaptimmune Therapeutics stock worth more than $2,235 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Norry may own. Additionally, Dr. Norry receives a salary of $676,190.00 as Insider at Adaptimmune Therapeutics. Learn More about Elliot Norry's net worth.
How old is Elliot Norry?: Dr. Norry is currently 60 years old. There are 5 older executives and no younger executives at Adaptimmune Therapeutics. Learn More on Elliot Norry's age.
What is Elliot Norry's salary?: As the Insider of Adaptimmune Therapeutics plc, Dr. Norry earns $676,190.00 per year. There are 2 executives that earn more than Dr. Norry. The highest earning executive at Adaptimmune Therapeutics is Mr. Adrian G. Rawcliffe, CEO, Principal Accounting Officer & Director, who commands a salary of $1,060,000.00 per year. Learn More on Elliot Norry's salary.
How do I contact Elliot Norry?: The corporate mailing address for Dr. Norry and other Adaptimmune Therapeutics executives is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. Adaptimmune Therapeutics can also be reached via phone at 441235430000 and via email at [email protected]. Learn More on Elliot Norry's contact information.
Has Elliot Norry been buying or selling shares of Adaptimmune Therapeutics?: Elliot Norry has not been actively trading shares of Adaptimmune Therapeutics within the last three months. Most recently, Elliot Norry sold 2,287 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $0.79, for a transaction totalling $1,806.73. Following the completion of the sale, the insider now directly owns 3,363 shares of the company's stock, valued at $2,656.77. Learn More on Elliot Norry's trading history.
Who are Adaptimmune Therapeutics' active insiders?: Adaptimmune Therapeutics' insider roster includes Willaim Bertrand, Jr. (COO), John Lunger (Insider), Elliot Norry (Insider), and Adrian Rawcliffe (CEO). Learn More on Adaptimmune Therapeutics' active insiders.
Are insiders buying or selling shares of Adaptimmune Therapeutics?: During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 61,977 shares worth more than $53,507.07. The most recent insider tranaction occured on June, 18th when insider Cintia Piccina sold 24,531 shares worth more than $22,813.83. Insiders at Adaptimmune Therapeutics own 12.4% of the company. Learn More about insider trades at Adaptimmune Therapeutics.
Information on this page was last updated on 6/18/2024.

Elliot Norry Insider Trading History at Adaptimmune Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	2,287	$0.79	$1,806.73	3,363
1/11/2024	Sell	4,009	$0.84	$3,367.56	6,104
1/18/2022	Sell	2,121	$3.19	$6,765.99
1/19/2021	Sell	2,111	$5.67	$11,969.37
1/14/2020	Sell	911	$5.13	$4,673.43

Elliot Norry Buying and Selling Activity at Adaptimmune Therapeutics

Adaptimmune Therapeutics Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $0.66

$0.64

$0.71

50 Day Range

MA: $0.85

$0.59

$1.11

2 Week Range

Now: $0.66

$0.42

$2.05

Volume

4,158,925 shs

Average Volume

1,733,154 shs

Market Capitalization

$170.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Elliot Norry Biography and Net Worth

What is Elliot Norry's net worth?

How old is Elliot Norry?

What is Elliot Norry's salary?

How do I contact Elliot Norry?

Has Elliot Norry been buying or selling shares of Adaptimmune Therapeutics?

Who are Adaptimmune Therapeutics' active insiders?

Are insiders buying or selling shares of Adaptimmune Therapeutics?